Current trends in autoimmunity and the nervous system

Journal of Autoimmunity

Volumn 75, Issue , 2016, Pages 20-29

  Selmi, Carlo ^a,b   Barin, Jobert G ^c   Rose, Noel R ^d  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Autoantibody; Autoimmune encephalitis; Central nervous system; Demyelination; Immune tolerance; Multiple sclerosis

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; AUTOANTIBODY;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; ENCEPHALOMYELITIS; HUMAN; IMMUNOLOGY; IMMUNOPATHOLOGY; MENTAL DISEASE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; BRAIN; CENTRAL NERVOUS SYSTEM; ENCEPHALITIS; HASHIMOTO DISEASE; IMMUNE SYSTEM; PERIPHERAL NERVOUS SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

AUTOANTIBODIES; AUTOIMMUNITY; BRAIN; CENTRAL NERVOUS SYSTEM; ENCEPHALITIS; HASHIMOTO DISEASE; HUMANS; IMMUNE SYSTEM; LUPUS ERYTHEMATOSUS, SYSTEMIC; MULTIPLE SCLEROSIS; PERIPHERAL NERVOUS SYSTEM;

EID: 84995550221     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.08.005     Document Type: Review

References (130)

1. [1] Hoftberger, R., Neuroimmunology: an expanding frontier in autoimmunity. Front. Immunol., 6, 2015, 206.
2. [2] Zlokovic, B.V., The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57 (2008), 178–201.
3. [3] Bynoe, M.S., Viret, C., Yan, A., Kim, D.G., Adenosine receptor signaling: a key to opening the blood-brain door. Fluids Barriers CNS, 12, 2015, 20.
4. [4] Obermeier, B., Daneman, R., Ransohoff, R.M., Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 19 (2013), 1584–1596.
5. [5] Ericsson, A., Liu, C., Hart, R.P., Sawchenko, P.E., Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J. Comp. Neurol. 361 (1995), 681–698.
6. [6] Vallieres, L., Rivest, S., Regulation of the genes encoding interleukin-6, its receptor, and gp130 in the rat brain in response to the immune activator lipopolysaccharide and the proinflammatory cytokine interleukin-1beta. J. Neurochem. 69 (1997), 1668–1683.
7. [7] Nadeau, S., Rivest, S., Effects of circulating tumor necrosis factor on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood-brain barrier. Neuroscience 93 (1999), 1449–1464.
8. [8] Varatharaj, A., Galea, I., The blood-brain barrier in systemic inflammation. Brain Behav. Immun., 2016.
9. [9] Mills, J.H., Thompson, L.F., Mueller, C., Waickman, A.T., Jalkanen, S., Niemela, J., et al. CD73 is required for efficient entry of lymphocytes into the central nervous system during experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 9325–9330.
10. [10] Carman, A.J., Mills, J.H., Krenz, A., Kim, D.G., Bynoe, M.S., Adenosine receptor signaling modulates permeability of the blood-brain barrier. J. Neurosci. 31 (2011), 13272–13280.
11. [11] Wojciak-Stothard, B., Potempa, S., Eichholtz, T., Ridley, A.J., Rho and Rac but not Cdc42 regulate endothelial cell permeability. J. Cell Sci. 114 (2001), 1343–1355.
12. [12] Dewi, B.E., Takasaki, T., Kurane, I., In vitro assessment of human endothelial cell permeability: effects of inflammatory cytokines and dengue virus infection. J. Virol. Methods 121 (2004), 171–180.
13. [13] Colgan, S.P., Eltzschig, H.K., Eckle, T., Thompson, L.F., Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal 2 (2006), 351–360.
14. [14] Narravula, S., Lennon, P.F., Mueller, B.U., Colgan, S.P., Regulation of endothelial CD73 by adenosine: paracrine pathway for enhanced endothelial barrier function. J. Immunol. 165 (2000), 5262–5268.
15. [15] Koszalka, P., Ozuyaman, B., Huo, Y., Zernecke, A., Flogel, U., Braun, N., et al. Targeted disruption of cd73/ecto-5'-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ. Res. 95 (2004), 814–821.
16. [16] Linden, J., Cell biology. Purinergic chemotaxis. Science 314 (2006), 1689–1690.
17. [17] Salmi, M., Jalkanen, S., Cell-surface enzymes in control of leukocyte trafficking. Nat. Rev. Immunol. 5 (2005), 760–771.
18. [18] Petrovic-Djergovic, D., Hyman, M.C., Ray, J.J., Bouis, D., Visovatti, S.H., Hayasaki, T., et al. Tissue-resident ecto-5 nucleotidase (CD73) regulates leukocyte trafficking in the ischemic brain. J. Immunol. 188 (2012), 2387–2398.
19. [19] Takedachi, M., Qu, D., Ebisuno, Y., Oohara, H., Joachims, M.L., McGee, S.T., et al. CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes. J. Immunol. 180 (2008), 6288–6296.
20. [20] Heppner, F.L., Greter, M., Marino, D., Falsig, J., Raivich, G., Hovelmeyer, N., et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11 (2005), 146–152.
21. [21] Greter, M., Heppner, F.L., Lemos, M.P., Odermatt, B.M., Goebels, N., Laufer, T., et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11 (2005), 328–334.
22. [22] Hemmer, B., Nessler, S., Zhou, D., Kieseier, B., Hartung, H.P., Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. Neurol. 2 (2006), 201–211.
23. [23] Alter, A., Duddy, M., Hebert, S., Biernacki, K., Prat, A., Antel, J.P., et al. Determinants of human B cell migration across brain endothelial cells. J. Immunol. 170 (2003), 4497–4505.
24. [24] Cserr, H.F., Harling-Berg, C.J., Knopf, P.M., Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. Brain Pathol. 2 (1992), 269–276.
25. [25] Kida, S., Pantazis, A., Weller, R.O., CSF drains directly from the subarachnoid space into nasal lymphatics in the rat. Anatomy, histology and immunological significance. Neuropathol. Appl. Neurobiol. 19 (1993), 480–488.
26. [26] Louveau, A., Smirnov, I., Keyes, T.J., Eccles, J.D., Rouhani, S.J., Peske, J.D., et al. Structural and functional features of central nervous system lymphatic vessels. Nature 523 (2015), 337–341.
27. [27] Aspelund, A., Antila, S., Proulx, S.T., Karlsen, T.V., Karaman, S., Detmar, M., et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J. Exp. Med. 212 (2015), 991–999.
28. [28] Louveau, A., Harris, T.H., Kipnis, J., Revisiting the mechanisms of CNS immune privilege. Trends Immunol. 36 (2015), 569–577.
29. [29] Kuhn, A., Landmann, A., The classification and diagnosis of cutaneous lupus erythematosus. J. Autoimmun. 48–49 (2014), 14–19.
30. [30] Yu, C., Gershwin, M.E., Chang, C., Diagnostic criteria for systemic lupus erythematosus: a critical review. J. Autoimmun. 48–49 (2014), 10–13.
31. [31] Ainiala, H., Loukkola, J., Peltola, J., Korpela, M., Hietaharju, A., The prevalence of neuropsychiatric syndromes in systemic lupus erythematosus. Neurology 57 (2001), 496–500.
32. [32] Bertsias, G.K., Boumpas, D.T., Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat. Rev. Rheumatol. 6 (2010), 358–367.
33. [33] Borowoy, A.M., Pope, J.E., Silverman, E., Fortin, P.R., Pineau, C., Smith, C.D., et al. Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. Semin. Arthritis Rheum. 42 (2012), 179–185.
34. [34] Unterman, A., Nolte, J.E., Boaz, M., Abady, M., Shoenfeld, Y., Zandman-Goddard, G., Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin. Arthritis Rheum. 41 (2011), 1–11.
35. [35] Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., McShane, D.J., Rothfield, N.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 25 (1982), 1271–1277.
36. [36] Ghodke-Puranik, Y., Niewold, T.B., Immunogenetics of systemic lupus erythematosus: a comprehensive review. J. Autoimmun. 64 (2015), 125–136.
37. [37] Ines, L., Duarte, C., Silva, R.S., Teixeira, A.S., Fonseca, F.P., da Silva, J.A., Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study. Rheumatol. Oxf. 53 (2014), 85–89.
38. [38] Hanly, J.G., ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 13 (2004), 861–864.
39. [39] Bertsias, G.K., Ioannidis, J.P., Aringer, M., Bollen, E., Bombardieri, S., Bruce, I.N., et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann. Rheum. Dis. 69 (2010), 2074–2082.
40. [40] Hanly, J.G., Neuropsychiatric lupus. Rheum. Dis. Clin. North Am. 31 (2005), 273–298.
41. [41] Jeltsch-David, H., Muller, S., Neuropsychiatric systemic lupus erythematosus: pathogenesis and biomarkers. Nat. Rev. Neurol. 10 (2014), 579–596.
42. [42] Ramirez, G.A., Lanzani, C., Bozzolo, E.P., Citterio, L., Zagato, L., Casamassima, N., et al. TRPC6 gene variants and neuropsychiatric lupus. J. Neuroimmunol. 288 (2015), 21–24.
43. [43] de Vries, B., Steup-Beekman, G.M., Haan, J., Bollen, E.L., Luyendijk, J., Frants, R.R., et al. TREX1 gene variant in neuropsychiatric systemic lupus erythematosus. Ann. Rheum. Dis. 69 (2010), 1886–1887.
44. [44] Namjou, B., Kothari, P.H., Kelly, J.A., Glenn, S.B., Ojwang, J.O., Adler, A., et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 12 (2011), 270–279.
45. [45] Katzav, A., Solodeev, I., Brodsky, O., Chapman, J., Pick, C.G., Blank, M., et al. Induction of autoimmune depression in mice by anti-ribosomal P antibodies via the limbic system. Arthritis Rheum. 56 (2007), 938–948.
46. [46] Matus, S., Burgos, P.V., Bravo-Zehnder, M., Kraft, R., Porras, O.H., Farias, P., et al. Antiribosomal-P autoantibodies from psychiatric lupus target a novel neuronal surface protein causing calcium influx and apoptosis. J. Exp. Med. 204 (2007), 3221–3234.
47. [47] Gomez-Puerta, J.A., Cervera, R., Diagnosis and classification of the antiphospholipid syndrome. J. Autoimmun. 48–49 (2014), 20–25.
48. [48] Raschi, E., Chighizola, C.B., Grossi, C., Ronda, N., Gatti, R., Meroni, P.L., et al. beta2-glycoprotein I, lipopolysaccharide and endothelial TLR4: three players in the two hit theory for anti-phospholipid-mediated thrombosis. J. Autoimmun. 55 (2014), 42–50.
49. [49] Hawro, T., Bogucki, A., Krupinska-Kun, M., Maurer, M., Wozniacka, A., Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-beta2GPI antibodies in patients with systemic lupus erythematosus. PLoS One, 10, 2015, e0119911.
50. [50] Dalmau, J., Tuzun, E., Wu, H.Y., Masjuan, J., Rossi, J.E., Voloschin, A., et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann. Neurol. 61 (2007), 25–36.
51. [51] Lancaster, E., Lai, M., Peng, X., Hughes, E., Constantinescu, R., Raizer, J., et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 9 (2010), 67–76.
52. [52] Lai, M., Hughes, E.G., Peng, X., Zhou, L., Gleichman, A.J., Shu, H., et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann. Neurol. 65 (2009), 424–434.
53. [53] Leypoldt, F., Armangue, T., Dalmau, J., Autoimmune encephalopathies. Ann. N. Y. Acad. Sci. 1338 (2015), 94–114.
54. [54] Gresa-Arribas, N., Titulaer, M.J., Torrents, A., Aguilar, E., McCracken, L., Leypoldt, F., et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 13 (2014), 167–177.
55. [55] Titulaer, M.J., McCracken, L., Gabilondo, I., Armangue, T., Glaser, C., Iizuka, T., et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 12 (2013), 157–165.
56. [56] Sabater, L., Gaig, C., Gelpi, E., Bataller, L., Lewerenz, J., Torres-Vega, E., et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 13 (2014), 575–586.
57. [57] Noseworthy, J.H., Lucchinetti, C., Rodriguez, M., Weinshenker, B.G., Multiple sclerosis. N. Engl. J. Med. 343 (2000), 938–952.
58. [58] Karussis, D., The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J. Autoimmun. 48–49 (2014), 134–142.
59. [59] Hollenbach, J.A., Oksenberg, J.R., The immunogenetics of multiple sclerosis: a comprehensive review. J. Autoimmun. 64 (2015), 13–25.
60. [60] Selmi, C., Mix, E., Zettl, U.K., A clear look at the neuroimmunology of multiple sclerosis and beyond. Autoimmun. Rev. 11 (2012), 159–162.
61. [61] Steinman, L., Shoenfeld, Y., From defining antigens to new therapies in multiple sclerosis: honoring the contributions of Ruth Arnon and Michael Sela. J. Autoimmun. 54 (2014), 1–7.
62. [62] Ben-Nun, A., Kaushansky, N., Kawakami, N., Krishnamoorthy, G., Berer, K., Liblau, R., et al. From classic to spontaneous and humanized models of multiple sclerosis: impact on understanding pathogenesis and drug development. J. Autoimmun. 54 (2014), 33–50.
63. [63] Gay, F.W., Drye, T.J., Dick, G.W., Esiri, M.M., The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 120:Pt 8 (1997), 1461–1483.
64. [64] Cannella, B., Raine, C.S., The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 37 (1995), 424–435.
65. [65] Trapp, B.D., Peterson, J., Ransohoff, R.M., Rudick, R., Mork, S., Bo, L., Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338 (1998), 278–285.
66. [66] Duraes, F.V., Lippens, C., Steinbach, K., Dubrot, J., Brighouse, D., Bendriss-Vermare, N., et al. pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation. J. Autoimmun., 2015.
67. [67] Pette, M., Fujita, K., Kitze, B., Whitaker, J.N., Albert, E., Kappos, L., et al. Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 40 (1990), 1770–1776.
68. [68] Bar-Or, A., Fawaz, L., Fan, B., Darlington, P.J., Rieger, A., Ghorayeb, C., et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?. Ann. Neurol. 67 (2010), 452–461.
69. [69] Barr, T.A., Shen, P., Brown, S., Lampropoulou, V., Roch, T., Lawrie, S., et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 209 (2012), 1001–1010.
70. [70] Ireland, S.J., Guzman, A.A., Frohman, E.M., Monson, N.L., B cells from relapsing remitting multiple sclerosis patients support neuro-antigen-specific Th17 responses. J. Neuroimmunol. 291 (2016), 46–53.
71. [71] Safarzadeh, E., Jadidi-Niaragh, F., Motallebnezhad, M., Yousefi, M., The role of adenosine and adenosine receptors in the immunopathogenesis of multiple sclerosis. Inflamm. Res. 65 (2016), 511–520.
72. [72] Johnston, J.B., Silva, C., Gonzalez, G., Holden, J., Warren, K.G., Metz, L.M., et al. Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann. Neurol. 49 (2001), 650–658.
73. [73] Stone, T.W., Ceruti, S., Abbracchio, M.P., Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb. Exp. Pharmacol., 2009, 535–587.
74. [74] Chen, J.F., Sonsalla, P.K., Pedata, F., Melani, A., Domenici, M.R., Popoli, P., et al. Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. Prog. Neurobiol. 83 (2007), 310–331.
75. [75] Torkildsen, O., Myhr, K.M., Bo, L., Disease-modifying treatments for multiple sclerosis - a review of approved medications. Eur. J. Neurol. 23:1 (2016), 18–27.
76. [76] Dhib-Jalbut, S., Marks, S., Interferon-beta mechanisms of action in multiple sclerosis. Neurology 74:1 (2010), S17–S24.
77. [77] Racke, M.K., Lovett-Racke, A.E., Karandikar, N.J., The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 74:1 (2010), S25–S30.
78. [78] Papadopoulou, A., Kappos, L., Sprenger, T., Teriflunomide for oral therapy in multiple sclerosis. Expert Rev. Clin. Pharmacol. 5 (2012), 617–628.
79. [79] Linker, R.A., Gold, R., Dimethyl fumarate for treatment of multiple sclerosis: mechanism of action, effectiveness, and side effects. Curr. Neurol. Neurosci. Rep., 13, 2013, 394.
80. [80] Polman, C.H., O'Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354 (2006), 899–910.
81. [81] Kappos, L., Radue, E.W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 362 (2010), 387–401.
82. [82] Brown, J.W., Coles, A.J., Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. Drug Des. Devel Ther. 7 (2013), 131–138.
83. [83] Milo, R., Therapeutic strategies targeting B-cells in multiple sclerosis. Autoimmun. Rev. 15 (2016), 714–718.
84. [84] van Os, J., Kapur, S., Schizophrenia. Lancet 374 (2009), 635–645.
85. [85] Pathmanandavel, K., Starling, J., Dale, R.C., Brilot, F., Autoantibodies and the immune hypothesis in psychotic brain diseases: challenges and perspectives. Clin. Dev. Immunol., 2013, 2013, 257184.
86. [86] Friston, K.J., Schizophrenia and the disconnection hypothesis. Acta Psychiatr. Scand. Suppl. 395 (1999), 68–79.
87. [87] Severance, E.G., Yolken, R.H., Eaton, W.W., Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr. Res., 2014.
88. [88] Cascella, N.G., Kryszak, D., Bhatti, B., Gregory, P., Kelly, D.L., Mc Evoy, J.P., et al. Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. Schizophr. Bull. 37 (2011), 94–100.
89. [89] Samaroo, D., Dickerson, F., Kasarda, D.D., Green, P.H., Briani, C., Yolken, R.H., et al. Novel immune response to gluten in individuals with schizophrenia. Schizophr. Res. 118 (2010), 248–255.
90. [90] Porcelli, B., Verdino, V., Bossini, L., Terzuoli, L., Fagiolini, A., Celiac and non-celiac gluten sensitivity: a review on the association with schizophrenia and mood disorders. Auto. Immun. Highlights 5 (2014), 55–61.
91. [91] Palova-Jelinkova, L., Rozkova, D., Pecharova, B., Bartova, J., Sediva, A., Tlaskalova-Hogenova, H., et al. Gliadin fragments induce phenotypic and functional maturation of human dendritic cells. J. Immunol. 175 (2005), 7038–7045.
92. [92] Thomas, K.E., Sapone, A., Fasano, A., Vogel, S.N., Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: role of the innate immune response in Celiac disease. J. Immunol. 176 (2006), 2512–2521.
93. [93] Jackson, J.R., Eaton, W.W., Cascella, N.G., Fasano, A., Kelly, D.L., Neurologic and psychiatric manifestations of celiac disease and gluten sensitivity. Psychiatr. Q. 83 (2012), 91–102.
94. [94] Hadjivassiliou, M., Grunewald, R., Sharrack, B., Sanders, D., Lobo, A., Williamson, C., et al. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. Brain 126 (2003), 685–691.
95. [95] Boscolo, S., Sarich, A., Lorenzon, A., Passoni, M., Rui, V., Stebel, M., et al. Gluten ataxia: passive transfer in a mouse model. Ann. N. Y. Acad. Sci. 1107 (2007), 319–328.
96. [96] Jackson, J., Eaton, W., Cascella, N., Fasano, A., Warfel, D., Feldman, S., et al. A gluten-free diet in people with schizophrenia and anti-tissue transglutaminase or anti-gliadin antibodies. Schizophr. Res. 140 (2012), 262–263.
97. [97] Griffin, D.E., Viral encephalomyelitis. PLoS Pathog., 7, 2011, e1002004.
98. [98] Glaser, C.A., Honarmand, S., Anderson, L.J., Schnurr, D.P., Forghani, B., Cossen, C.K., et al. Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin. Infect. Dis. 43 (2006), 1565–1577.
99. [99] Griffin, D.E., Emergence and re-emergence of viral diseases of the central nervous system. Prog. Neurobiol. 91 (2010), 95–101.
100. [100] Ugolini, G., Use of rabies virus as a transneuronal tracer of neuronal connections: implications for the understanding of rabies pathogenesis. Dev. Biol. (Basel) 131 (2008), 493–506.
101. [101] Lyman, M.G., Enquist, L.W., Herpesvirus interactions with the host cytoskeleton. J. Virol. 83 (2009), 2058–2066.
102. [102] Havert, M.B., Schofield, B., Griffin, D.E., Irani, D.N., Activation of divergent neuronal cell death pathways in different target cell populations during neuroadapted sindbis virus infection of mice. J. Virol. 74 (2000), 5352–5356.
103. [103] Conrady, C.D., Drevets, D.A., Carr, D.J., Herpes simplex type I (HSV-1) infection of the nervous system: is an immune response a good thing?. J. Neuroimmunol. 220 (2010), 1–9.
104. [104] Greene, I.P., Lee, E.Y., Prow, N., Ngwang, B., Griffin, D.E., Protection from fatal viral encephalomyelitis: AMPA receptor antagonists have a direct effect on the inflammatory response to infection. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 3575–3580.
105. [105] Griffin, D.E., Recovery from viral encephalomyelitis: immune-mediated noncytolytic virus clearance from neurons. Immunol. Res. 47 (2010), 123–133.
106. [106] Vernon, P.S., Griffin, D.E., Characterization of an in vitro model of alphavirus infection of immature and mature neurons. J. Virol. 79 (2005), 3438–3447.
107. [107] Burdeinick-Kerr, R., Govindarajan, D., Griffin, D.E., Noncytolytic clearance of sindbis virus infection from neurons by gamma interferon is dependent on Jak/STAT signaling. J. Virol. 83 (2009), 3429–3435.
108. [108] Ubol, S., Levine, B., Lee, S.H., Greenspan, N.S., Griffin, D.E., Roles of immunoglobulin valency and the heavy-chain constant domain in antibody-mediated downregulation of Sindbis virus replication in persistently infected neurons. J. Virol. 69 (1995), 1990–1993.
109. [109] Levine, B., Hardwick, J.M., Trapp, B.D., Crawford, T.O., Bollinger, R.C., Griffin, D.E., Antibody-mediated clearance of alphavirus infection from neurons. Science 254 (1991), 856–860.
110. [110] Tyor, W.R., Wesselingh, S., Levine, B., Griffin, D.E., Long term intraparenchymal Ig secretion after acute viral encephalitis in mice. J. Immunol. 149 (1992), 4016–4020.
111. [111] Pavlov, V.A., Tracey, K.J., Neural circuitry and immunity. Immunol. Res. 63 (2015), 38–57.
112. [112] Chiu, I.M., von Hehn, C.A., Woolf, C.J., Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nat. Neurosci. 15 (2012), 1063–1067.
113. [113] Ordovas-Montanes, J., Rakoff-Nahoum, S., Huang, S., Riol-Blanco, L., Barreiro, O., von Andrian, U.H., The regulation of immunological processes by peripheral neurons in homeostasis and disease. Trends Immunol. 36 (2015), 578–604.
114. [114] Borovikova, L.V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G.I., Watkins, L.R., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405 (2000), 458–462.
115. [115] Pongratz, G., Straub, R.H., Role of peripheral nerve fibres in acute and chronic inflammation in arthritis. Nat. Rev. Rheumatol. 9 (2013), 117–126.
116. [116] Lorton, D., Lubahn, C., Klein, N., Schaller, J., Bellinger, D.L., Dual role for noradrenergic innervation of lymphoid tissue and arthritic joints in adjuvant-induced arthritis. Brain Behav. Immun. 13 (1999), 315–334.
117. [117] Harle, P., Mobius, D., Carr, D.J., Scholmerich, J., Straub, R.H., An opposing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the local lymph nodes and spleen of mice with type II collagen-induced arthritis. Arthritis Rheum. 52 (2005), 1305–1313.
118. [118] Pongratz, G., Melzer, M., Straub, R.H., The sympathetic nervous system stimulates anti-inflammatory B cells in collagen-type II-induced arthritis. Ann. Rheum. Dis. 71 (2012), 432–439.
119. [119] Lombardi, M.S., Kavelaars, A., Cobelens, P.M., Schmidt, R.E., Schedlowski, M., Heijnen, C.J., Adjuvant arthritis induces down-regulation of G protein-coupled receptor kinases in the immune system. J. Immunol. 166 (2001), 1635–1640.
120. [120] Straub, R.H., Grum, F., Strauch, U., Capellino, S., Bataille, F., Bleich, A., et al. Anti-inflammatory role of sympathetic nerves in chronic intestinal inflammation. Gut 57 (2008), 911–921.
121. [121] Naukkarinen, A., Nickoloff, B.J., Farber, E.M., Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J. Invest Dermatol 92 (1989), 126–129.
122. [122] Miller, L.E., Justen, H.P., Scholmerich, J., Straub, R.H., The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J. 14 (2000), 2097–2107.
123. [123] Bruno, R.M., Ghiadoni, L., Seravalle, G., Dell'oro, R., Taddei, S., Grassi, G., Sympathetic regulation of vascular function in health and disease. Front. Physiol., 3, 2012, 284.
124. [124] Ellebrecht, C.T., Srinivas, G., Bieber, K., Banczyk, D., Kalies, K., Kunzel, S., et al. Skin microbiota-associated inflammation precedes autoantibody induced tissue damage in experimental epidermolysis bullosa acquisita. J. Autoimmun., 2015.
125. [125] Peng, J., Narasimhan, S., Marchesi, J.R., Benson, A., Wong, F.S., Wen, L., Long term effect of gut microbiota transfer on diabetes development. J. Autoimmun. 53 (2014), 85–94.
126. [126] Matelski, L., Van de Water, J., Risk factors in autism: thinking outside the brain. J. Autoimmun., 2015.
127. [127] Luna, R.A., Savidge, T.C., Williams, K.C., The brain-gut-microbiome axis: what role does it play in autism spectrum disorder?. Curr. Dev. Disord. Rep. 3 (2016), 75–81.
128. [128] Berrih-Aknin, S., Myasthenia Gravis: paradox versus paradigm in autoimmunity. J. Autoimmun. 52 (2014), 1–28.
129. [129] Zisimopoulou, P., Evangelakou, P., Tzartos, J., Lazaridis, K., Zouvelou, V., Mantegazza, R., et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J. Autoimmun. 52 (2014), 139–145.
130. [130] Berrih-Aknin, S., Frenkian-Cuvelier, M., Eymard, B., Diagnostic and clinical classification of autoimmune myasthenia gravis. J. Autoimmun. 48–49 (2014), 143–148.